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Abstract:  28 
Pseudomonas aeruginosa causes chronic lung infections in people with cystic fibrosis (CF) and acute 29 
opportunistic infections in people without CF.  Forty two P. aeruginosa strains from a range of 30 
clinical and environmental sources were collated into a single reference strain panel to harmonise 31 
research on this diverse opportunistic pathogen.  To facilitate further harmonized and comparable 32 
research on P. aeruginosa, we characterised the panel strains for growth rates, motility, virulence in 33 
the Galleria mellonella infection model, pyocyanin and alginate production, mucoid phenotype, 34 
lipopolysaccharide (LPS) pattern, biofilm formation, urease activity,  antimicrobial and phage 35 
susceptibilities.  Phenotypic diversity across the P. aeruginosa panel was apparent for all phenotypes 36 
examined agreeing with the marked variability seen in this species.  However, except for growth 37 
rate, the phenotypic diversity among strains from CF versus non-CF sources was comparable.  CF 38 
strains were less virulent in the G. mellonella model than non-CF strains (p=0.037). Transmissible CF 39 
strains generally lacked O antigen, produced less pyocyanin, and had low virulence in G. mellonella.  40 
Further, in the three sets of sequential CF strains, virulence, O-antigen expression and pyocyanin 41 
production were higher in the earlier isolate compared to the isolate obtained later in infection.  42 
Overall, full phenotypic characterization of the defined panel of P. aeruginosa strains increases our 43 
understanding of the virulence and pathogenesis of P. aeruginosa and provides a valuable resource 44 
for the testing of novel therapies against this problematic pathogen.  45 
 46 
  47 
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INTRODUCTION 48 
Pseudomonas aeruginosa is a Gram-negative bacterium that causes opportunistic infections 49 
including burn wound infections, urinary tract infections, keratitis, otitis externa and respiratory 50 
tract infections in susceptible individuals.  P. aeruginosa is a major pulmonary pathogen in people 51 
with cystic fibrosis (CF), contributing significantly to their observed decline in lung function and 52 
morbidity, with over 50% of people with CF being chronically colonised by adulthood.  Most of the 53 
extensive research carried out on P. aeruginosa has focussed on selected strains (e.g. PAO1 or 54 
PA14), several of which are genotypically distinct from the more abundant clinical strains (De Soyza 55 
et al., 2013).  It has been widely demonstrated that P. aeruginosa is a highly diverse species 56 
(Fothergill et al., 2010; Mowat et al., 2011). Given the diversity and adaptability of P. aeruginosa in a 57 
broad range of environments, including non-clinical settings such as soil, lake water and plants, 58 
research focusing on a single or very small number of strains may lead to conclusions that are not 59 
relevant to the clinical scenario or the infection being examined.  To address this, we collated an 60 
international P. aeruginosa reference panel allowing better consolidation of research into the 61 
pathogenesis of this organism (De Soyza et al., 2013).  Certain P. aeruginosa strains from CF patients 62 
are genotypically indistinguishable from environmental strains despite the extensive differences in 63 
habitats (Wiehlmann et al., 2007).  Therefore, the panel comprised 42 strains that were selected to 64 
represent the diversity across P. aeruginosa and included strains from a wide variety of clinical and 65 
environmental sources.  In addition, strains from a range of geographical regions, transmissible 66 
(epidemic) CF strains and representatives of sequential strains from early to late (i.e. chronic) CF 67 
infection were incorporated into the panel (De Soyza et al., 2013).  68 
Several panel strains have been studied previously and specific virulence properties and other traits 69 
have been examined in individual strains or compared across small groups of strains.  Here, we 70 
report the standardised phenotypic characterisation of the panel, including growth characteristics, 71 
motility, virulence in Galleria mellonella, production of alginate and virulence factors, including 72 
pyocyanin and LPS; urease activity, biofilm formation, quorum sensing (QS), antibiotic resistance and 73 
phage susceptibility.  Our aims were to facilitate the future use of this panel for broad comparisons 74 
across a wide range of phenotypes and to compare the strains of CF and non-CF origin for 75 
phenotypic differences that depend on their particular niches.      76 
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METHODS 77 
Growth conditions. The strain panel is available from the BCCM/LMG Bacteria Collection, Gent, 78 
Belgium, (http://bccm.belspo.be/about/lmg.php) (Table 1) (De Soyza et al., 2013).  The original panel 79 
comprised of 43 strains; however, strain NN2 was withdrawn from the BCCM collection and 80 
excluded from this study due to inconsistencies in its taxonomic identity when it was shared across 81 
the multiple laboratories who participated in the current research.  Strains were routinely grown on 82 
Tryptone Soya Agar (TSA; Oxoid Ltd., UK) overnight (16-18 h) at 37°C. Overnight broth cultures were 83 
prepared by inoculating 3 ml Luria Bertani broth (LB; Oxoid) with fresh growth from a pure streak 84 
plate. Cultures were grown for 16-18 h at 37°C, shaking at 150 rpm.  85 
 86 
Growth curve analysis. Growth was examined on a Bioscreen C instrument (Labsystems, Finland) in 87 
200 µl Mueller-Hinton broth (MHB) inoculated with approximately 105 cfu ml–1.  Growth in liquid 88 
culture was monitored for 48 h at 37°C and turbidity measurements were taken every 15 min after 89 
shaking the microplates for 10 sec.  A scatterplot was used to visualise growth curves and the growth 90 
parameters were analysed with the grofit package (Kahm et al., 2010) using R statistical software (R-91 
Core-Team, 2013).  Strains producing growth curves which could not be modelled accurately by 92 
grofit (discordance between model and model-free-spline fits) were excluded. The distribution of 93 
growth parameter data was examined with BoxPlotR (Michaela et al., 2014).  94 
 95 
Virulence in the G. mellonella insect infection model.  Virulence was determined according to 96 
published methods (Lore et al., 2012), with some modifications. Wax moth larvae (Livefoods Direct, 97 
Sheffield, UK) were stored at 15oC and used within 4 weeks. Overnight bacterial cultures in LB were 98 
diluted 1:10 and grown to an OD600nm of 0.4-0.8. Cultures were centrifuged and bacterial cells 99 
resuspended in 10 mM MgSO4 (Sigma-Aldrich) and serially diluted to 10
-9.  Each dilution was injected 100 
(10 µl) into the hindmost proleg of healthy larvae (6 per group).  The same volume of MgSO4 was 101 
injected into one group as a control.  To preserve the mucoid phenotype of IST27, it and its non-102 
mucoid revertant were serially diluted directly from Pseudomonas Isolation Agar (PIA) plates prior to 103 
infection.   Bioburden was determined by plating 10 µl of each dilution onto LB agar and colonies 104 
counted after 24 h. Injected larvae were incubated at 37oC for 24 h and LD50 values determined using 105 
log graph paper.   106 
 107 
Motility assays. Agar concentrations were prepared by adding molecular biology grade agarose 108 
(Severn Biotech Ltd., UK) to either LB or Basal Salts Medium supplemented with 0.4% (w/v) glucose 109 
(BSM-G) and all agar plates were poured on an even surface. At least two biological replicates per 110 
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strain were performed for each assay (Rashid & Kornberg, 2000).  Swimming motility was assessed 111 
by inoculating the surface of a 0.3% (w/v) LB agar plate with overnight culture using a sterile 112 
toothpick. Swimming plates were incubated overnight at 37°C for 16-18 hours. Media used to assess 113 
swarming motility were 0.5% (w/v) LB agar and BSM-G agar. Swarming plates were surface 114 
inoculated with growth from an overnight culture using a sterile toothpick,  incubated at 30°C for 16-115 
18 h. The diameters of the swimming and swarming zones were calculated by taking an average of 116 
two perpendicular measurements. Strains were scored as non-motile (diameter ≤ 5 mm), motile 117 
(diameter > 5 mm and ≤ 60 mm), or highly motile (diameter > 60 mm) in swimming and swarming 118 
assays. 119 
Twitching motility was assessed using 1% (w/v) LB agar. Twitch plates were stab inoculated to 120 
the base of the petri dish with an overnight culture. Following incubation for 16-18 h at 37°C, twitch 121 
plates were dried and agar removed before zones of motility at the agar/petri dish interface were 122 
stained with 0.5% (w/v) Coomassie brilliant blue R250 (Sigma-Aldrich) for 2 min (McMichael, 1992).  123 
After removal of excess stain, diameter of twitching zones was calculated by taking an average of 124 
two perpendicular measurements.  Strains were scored as non-motile (diameter ≤ 5 mm), motile 125 
(diameter > 5 mm and ≤ 30 mm), or highly motile (diameter > 30 mm). 126 
 127 
Auxotrophy.  Approximately 50,000 cells were spotted on either Mueller Hinton Agar (MHA) or 128 
Davis Minimal Agar (DMA). The strains that grew on both media were considered prototrophs, 129 
whereas those growing on MHA but not on DMA were considered auxotrophs and subjected to 130 
further analysis. Identification of specific amino acid requirements was done using DMA 131 
supplemented with: 1) single or multiple amino acids at concentrations of 20 μg ml–1; or 2) 132 
combinations of 19 amino acids at 20 μg ml–1 (Fluka, Switzerland) (Barth & Pitt, 1995).  Control agar, 133 
such as MHA and DMA without amino acids, was included in all tests; plates were incubated at 37oC 134 
for 48 h.  135 
 136 
Production of N-acyl homoserine lactones (AHLs). AHL production was determined using two 137 
biosensor strains (Escherichia coli JB523 and P. aeruginosa QSIS2) (Brackman et al., 2009).  138 
Supernatants of 24-h P. aeruginosa cultures grown in MHB at 37°C were added to the biosensor 139 
strains and fluorescence (JB523 assay, ex 475 nm; em  515 nm) or absorbance (QSIS2 assay) was 140 
measured using an Envision Xcite multilabel platereader (Perkin Elmer).  For the JB523 assay, which 141 
produces green fluorescent protein [GFP] in response to the presence of QS molecules, data were 142 
presented as background corrected fluorescence values. These values were obtained by subtracting 143 
the fluorescence measured in the sensor strain to which uninoculated MHB was added from the 144 
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value measured for each strain. This biosensor is most sensitive to 3-oxo-C6-homoserine lactone 145 
(HSL), C6-HSL and 3-oxo-C8 HSL. In the QSIS2 assay, growth was repressed by the presence of QS 146 
molecules (mainly 3-oxo-C12 HSL). For this assay, the control to which 200 nM of 3-oxo-C12-HSL and 147 
C4-HSL (each) was added was set as “100% QS” and the control to which no N-acyl-HSL or 148 
supernatant was added, was set as “0% QS”. 149 
 150 
Biofilm formation. Each strain was loop-inoculated from agar slants into LB (5 ml) and cultured 151 
overnight. Aliquots were diluted 1:100 in 10 ml of either MHB, LB or glucose-supplemented M63 152 
medium (M63) composed of 0.02 M KH2PO4, 0.04 M K2HPO4, 0.02 M (NH4)2SO4, 0.1 mM MgSO4 and 153 
0.04 M glucose.  After mixing, 150 µl of bacterial suspension were inoculated into 96-well plates, 10 154 
wells per plate, per strain and incubated 37oC for 24, 48, or 72 h.  Media were aspirated and the 155 
wells washed thrice with PBS before staining with 0.1% crystal violet (CV) after which time the wells 156 
were washed with PBS until washes were clear. The CV was solubilized in 70% ethanol and 157 
absorbance measured at 570 nm.   158 
 159 
Pyocyanin production. Pyocyanin was determined as previously described (Essar et al., 1990) using 160 
PB medium (Bactopeptone, MgCl2, K2SO4) to maximize pyocyanin production in liquid culture, 161 
chloroform for extraction and subsequently HCl for re-extraction. The absorbance of the final 162 
solution was measured at 520 nm.   163 
 164 
Phage typing. Eight strictly lytic P. aeruginosa bacteriophages with sequenced genomes (Table S1) 165 
were used: LUZ7, LUZ19, LBL3, and φKZ, from the collection of the Laboratory of Gene Technology, 166 
KU Leuven, Belgium (Ceyssens & Lavigne, 2010), and newly isolated phages KT28, KTN6, KTN4,  and 167 
PA5oct from the Institute of Genetics and Microbiology collection, University of Wroclaw, Poland.  168 
Phage typing was performed following previously published methods (Adams, 1959; Kutter, 2009). 169 
Prior to phage sensitivity testing, bacteria were subcultured in TSB (Becton Dickinson, Cockeysville, 170 
MD) for 4 to 6 h. To determine bacterial susceptibility to phage-mediated lysis, bacteria grown on 171 
liquid TSB medium were transferred directly onto TSA. After drying, 10 µl of phage suspensions (104 172 
PFU ml–1) were applied and incubated at 37oC. The plates were checked for the presence of bacterial 173 
lysis.  174 
 175 
Antibiotic resistance. Minimum inhibitory concentrations were performed independently in two 176 
separate laboratories using two broth dilution methods, a commercial antibiotic panel TRIOS 177 
(Prague, Czech Republic), and Trek Diagnostics Sensititre (UK).  Results were read at 24 and 48 h. In 178 
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the instances where there was complete disagreement between these methods, E test MIC’s 179 
BioMérieux (UK) were also performed.  All results were interpreted following EUCAST guidelines 180 
(EUCAST, version 3.1, 11.2.2013; http://www.eucast.org/clinical_breakpoints).   181 
 182 
Quantification of urease activity. Individual strains were cultured overnight in Christensen broth at 183 
37 °C with shaking. Fresh Christensen broth was inoculated at a ratio of 1:100 (v/v) with overnight 184 
culture and re-cultured as above. Cultures were centrifuged (3000 g, 15 min) and the absorbance of 185 
cell supernatants at 560 nm measured in triplicate.   186 
 187 
LPS extraction and analysis. Overnight cultures were adjusted to an OD600 of 2.0 in PBS (1 ml).  Cells 188 
were lysed in 2% SDS, 4% β-mercaptoethanol and Tris (pH 6.8) and boiled for 10 min.  The lysates 189 
were treated with proteinase K at 60oC for 2 h and stored at -20oC. LPS was resolved by 190 
electrophoresis on 14% polyacrylamide/Glycine-SDS gels (Lesse et al., 1990; Schagger & von Jagow, 191 
1987) and visualised by silver staining (Marolda et al., 1990). 192 
 193 
Analysis of alginate production. Overnight cultures inoculated with single colonies of either the 194 
characteristic mucoid or nonmucoid phenotype, observed following 24-48 h of growth on PIA plates 195 
at 37oC, were adjusted to an OD600 of 2.0 in PBS.  Alginate production was determined by ethanol 196 
precipitation of the exopolysaccharide from cell-free supernatants and quantification of uronic acids 197 
by the modified carbazole method using sodium alginate from Laminaria hyperborean as standard 198 
(BDH Chemicals Ltd., Poole, England) (Knutson & Jeanes, 1968).  Alginate production based on 199 
bacterial growth on solid medium was also assessed using LB and PIA.  Plates were inoculated with 200 
100 µl of a cell suspension harvested during the exponential phase of growth and resuspended to 201 
obtain a standardized OD640 of 0.2 ± 0.02.  After growth for 24 h at 37
oC, cultures were scraped from 202 
the plates, resuspended in 0.9% NaCl and harvested at 20,000 g for 10 min and supernatants used 203 
for alginate quantification.   204 
 205 
Statistical analysis. Unless otherwise indicated all statistical analyses were performed using Minitab 206 
statistical software package (v15). The distribution of each quantifiable phenotype was determined 207 
by plotting the mean data against the frequency in histograms. To confirm the data distribution 208 
observed, an Anderson Darling Test for Normality was performed (p<0.05, considered non-209 
normal).  Virulence, swimming, swarming on LB and BSM-G agar, AHL, alginate and pyocyanin 210 
production, growth rate and biofilm formation on MH, LB and M63 media were all found to have 211 
non-normal data distribution. Twitching motility and lag-phase phenotypes followed a normal data 212 
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distribution.   In addition, the effect of source of the strain (i.e. CF versus non-CF), on phenotype was 213 
determined using a general linear model for normally distributed data and Kruskal-Wallis analysis for 214 
non-normal distribution.  A total of 25 strains were in the CF group and 17 in the non-CF group, 215 
including both environmental and non-CF clinical strains. To determine if strain source had an effect 216 
on mean data variability, a test for equal variances was carried out by the F-test for normally 217 
distributed data and by Levene’s test in the cases of non-normally distributed data.      218 
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RESULTS 219 
Growth curve analysis 220 
The growth curves (Fig. S1) revealed considerable variability in the growth dynamics of each strain.  221 
The majority of the strains reached their maximum optical density by 15 h and could be split into 222 
two groups: one reaching a higher optical density (> 0.25) and the other reaching a lower density (< 223 
0.20) (Table 1). This has been illustrated in greater detail in the boxplot in Fig. 1(a), which resolved 224 
the maximum culture density data for the panel strains into two broad groups.  According to this 225 
analysis, only one strain (AMT 0023-34) was classified as having an intermediate maximum culture 226 
density at 15 h, while the others fell into high and low culture density groups.  The widely studied 227 
PAO1 strain reached the highest culture density within 15 h (Fig 1(a)).  228 
The grofit package for R statistical software was used to better model growth curve 229 
parameters (length of lag phase, maximum growth rate and maximum culture density reached), up 230 
to 30 h growth.  Most of the transmissible strains (LES B58, LES 400, LES 431 and C3719), in addition 231 
to NH57388A and Mil 162, had growth curves that could not be modelled accurately by grofit, 232 
possibly because of their long lag phase and/or poorly defined exponential phase.  Growth 233 
parameters for the remaining 36 strains are displayed in Table 2S and boxplots summarise the 234 
spread of the data (Fig. 1(b)).  Outliers indicated in the boxplots are strain 968333S, which had a 235 
longer lag phase (8.8 h) than the maximum value for all strains (upper whisker = 8.0 hours); 2192 236 
and AMT 0023-34. The latter two strains had longer lag phases (8.0 and 7.9 h, respectively) than the 237 
maximum value for CF strains (upper whisker = 7.48).  In addition, strains 968333S, AUS52, AUS23 238 
and UCBPP-PA14 reached a lower maximum OD (0.13, 0.16, 0.19 and 0.26, respectively) than the 239 
minimum value for all strains (lower whisker = 0.29).   240 
 241 
Autotrophy analysis 242 
Only four auxotrophs were identified in the panel.  The CF strain, AUS23 and bronchiectasis strain 243 
968333S required histidine, while the transmissible strain LES B58 required methionine and CF strain 244 
NH57388A required both isoleucine and valine.  In addition, the transmissible strain LES 400 was an 245 
apparent prototroph as it grew weakly on minimal medium, but grew abundantly in the presence of 246 
threonine.    247 
  248 
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Virulence in the G. mellonella model 249 
The majority of strains were virulent in G. mellonella with 31 strains showing LD50 values at 24 h of 250 
less than 5 CFU (Table 1).  Virulence was non-normally distributed (Anderson-Darling p<0.005).  251 
When strains that were isolated from CF sources were compared with those that were isolated from 252 
other sources, the most striking outcome was that CF strains were significantly less virulent in this 253 
acute infection model than strains that were not of CF origin (Kruskal-Wallis, p=0.037) (Fig 2).  254 
Furthermore, the CF transmissible strains showed considerably low virulence in G. mellonella, with 255 
six of the eight transmissible strains showing LD50s greater than 650 CFU.  Four of these strains (LES 256 
B58, LES400, LES431 and C3719) were also those that had long lag phase or poorly defined 257 
exponential phases.  In contrast, transmissible strains DK2 and AUS23 showed LD50 values ranging 258 
between 0.5-2 CFU.  The earliest identified LES strain (LES B58) was the most virulent of the three 259 
LES strains (LES B58, LES 400 and LES 431). The sequential CF strains (AA2, AA43 and AA44; 260 
AMT0023-30 and AMT0023-34; AMT0060-1, AMT0060-2 and AMT0060-3) showed a reduction in 261 
virulence over time of chronic infection (Fig 2), consistent with previous studies regarding niche 262 
adaptation of P. aeruginosa to the CF lung environment (Bragonzi et al., 2009; Lore et al., 2012).     263 
 264 
Motility of P. aeruginosa strains  265 
Motility was variable across the panel with the majority of strains (n=38) displaying at least one form 266 
of motility (Table 1, Fig S2).  The only observable general trend identified was a higher proportion of 267 
CF strains were non-motile compared to those from non-CF sources.  Four of the five non-motile 268 
strains (LES 400, LES 431, C3719 and AUS52), and four of the five strains capable of only swimming 269 
(LES B58, AES-1R, AMT 0023-34 and AMT 0060-2) were CF strains.  Furthermore, two of the three 270 
sets of sequential strains showed a loss in motility over time of colonisation; strain AMT 0060-3 271 
showed more swarming, swimming and twitching motilities relative to the later strain, AMT 0060-272 
02; while AMT 0023-30 showing more swarming and twitching motility relative to the later strain, 273 
AMT 0023-34. Only two strains (IST 27 mucoid and IST 27N) demonstrated ‘true’ swarming, 274 
indicated by the formation of finger-like projections radiating from the inoculation point (Fig. S2).     275 
 276 
AHL production 277 
AHL production was assessed using two biosensors with different sensitivities for various types of 278 
AHLs (Fig. 3).  Given that they are biosensors and are based on entirely different principles, they 279 
inherently show some variation. Although a direct comparison of results obtained with the two 280 
sensors used is difficult, some general trends emerge.   Under the conditions tested, the panel shows 281 
wide variation in the AHL levels produced.  The supernatants of some strains showed very low 282 
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signals in both assays (e.g. C3719, AUS23, LMG 14084), while other strains were identified as 283 
producers of high levels of AHLs by both systems (AMT 0060-3, IST 27 mucoid, IST 27N, 679, Pr335, 284 
U018a, 15108/1 and TBCF10839).  Strain 679 (isolated from urine) produced the highest levels as 285 
determined by the QSIS2 assay, while RP1 (a CF strain) produced the highest levels in the JB523 286 
assay. There was no correlation between AHL levels and the source of the strains.  AHL levels did not 287 
correlate with time of colonization in sequential CF strains, for example the early strain AA2 and the 288 
late strain AA43 both gave low signals in the QSIS2 assay, while the signal from another late strain 289 
(AA44) was much higher.   290 
 291 
Biofilm formation.   292 
Biofilm growth was compared in three media at three time points.  All strains formed biofilm to 293 
various degrees depending on medium and time (Table S3).  Overall, the majority of strains were 294 
generally good biofilm producers, including the majority of CF strains (Fig. 4).  There was no 295 
correlation between biofilm formation at 48 h and the source of the strains (CF v’s non-CF), nor were 296 
there any apparent differences in diversity between these two groups (Levene’s test, p=0.102).  The 297 
strains could be divided into poor biofilm-formers (A570 < 0.350), intermediate biofilm-formers (A570 298 
0.350 to 0.950) and extensive biofilm-formers (A570 > 0.950).  The only weak biofilm former among 299 
the CF strains was LES 431, which agrees with a previous report (Carter et al., 2010).  Of the other CF 300 
strains, seven were intermediate biofilm formers, and the rest were extensive biofilm formers. The 301 
weakest biofilm-former among the non-CF strains was the water isolate, LMG 14084. 302 
Time was an important parameter: rapid biofilm formers tend to detach over time, while 303 
slow biofilm formers steadily increased biofilm biomass until day 3 (Table S3). Therefore 304 
comparisons between the biofilm formation capacities of strains should take into account the strain-305 
specific kinetics of biofilm formation.  Strains with lower biofilm formation generally produced low 306 
or undetectable levels of AHLs, e.g. LMG14084, MI162, NH57388A, AA43, AES-1R, LES431, LES400, 307 
PR335, LES B58).  Further, strong biofilms were obtained for strains with relatively higher AHL levels 308 
(e.g. IST27N, 968333S, AA44, KK1).  However, this correlation was not always apparent, e.g. CHA 309 
(strong biofilm, low AHL), AUS52 (strong biofilm, no AHL) and PA679 (moderate biofilm, high AHL), 310 
indicating that other factors, in addition  to AHL production or the presence of an active QS system, 311 
play a role in biofilm formation of P. aeruginosa under these conditions.  312 
 313 
Pyocyanin production 314 
Pyocyanin is a major virulence factor of P. aeruginosa (Dietrich et al., 2006) and its production was 315 
variable across the panel (Table 1).  Low pyocyanin was observed in 22 strains (A520 < 0.1) with 14 316 
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strains producing very low levels (A520< 0.05). In contrast, nine strains showed comparatively high 317 
levels of pyocyanin (A520 > 0.3) (Fig. 5).  The pyocyanin levels in the sequential CF strains were lower 318 
in the later strain than in the early strain, suggesting that P. aeruginosa down-regulates pyocyanin 319 
production over time during chronic infection.  Most of CF transmissible strains (excluding LES B58 320 
and LES 431) produced negligible amounts of pyocyanin.  The serotype 1 strains (Pr335, U018a, CPHL 321 
9433 and 39177) showed very high levels of pyocyanin.  There were no significant differences in 322 
pyocyanin between CF and non-CF strains as determined by Kruskal-Wallis test (p=0.220), and both 323 
CF and non-CF populations showed comparable variation in levels of pyocyanin production (Levene’s 324 
test, p=0.237).  There was no clear correlation between pyocyanin and AHL levels, even though 325 
pyocyanin is considered to be QS-regulated.  Although many strains with very low levels of 326 
pyocyanin production only produced low or undetectable levels of AHL and several strains that 327 
produced higher levels of pyocyanin produced moderate to high levels of AHL , there were several 328 
strains that showed high pyocyanin levels but with low AHL levels (AA2, LMG14084 and 1709-12) 329 
and five that produced low pyocyanin, despite high AHL levels (PA968333S, IST27-N, RP1, KK1, 330 
AA44).  331 
 332 
LPS characterisation   333 
LPS is a major virulence factor in P. aeruginosa and consists of lipid A, core oligosaccharide and the 334 
highly variable long-chain O-polysaccharide (O-antigen) (Kocincova & Lam, 2011). Some P. 335 
aeruginosa strains, including PAO1, simultaneously produce two types of structurally and 336 
serologically distinct O-antigens in the same cell (A- and B- bands). The A-band is homopolymeric, 337 
while the B-band is heteropolymeric and responsible for serotype specificity.  In this study, the two 338 
O-antigen bands of PAO1 were detected (Fig. 6), while another commonly used strain UCBPP-PA14 339 
lacks the O-antigen the A-band, as previously described (Coulon et al., 2010). PAK and CHA also 340 
showed an LPS pattern similar to that previously described (Bezuidt et al., 2013; Rahim et al., 2000).    341 
During CF chronic infections, the O-antigen portion of LPS is often lost (Smith et al., 2006). 342 
Indeed, strains LES B58, LES 400 and LES 431, recovered during CF infections, did not exhibit O-343 
antigen, which is in agreement with the previous hypothesis that these strains contain rough LPS 344 
(Winstanley et al., 2009). Two other transmissible strains also lacked O-antigen, C3719 and DK2, in 345 
contrast to AES-1R and AUS23, also transmissible strains (Fig. 6).  The LPS of the sequential strains 346 
AA2 (early isolate), AA43 and AA44 (late isolates) is complete and shows an identical O-antigen 347 
repeating unit in all three strains, as previously reported (Cigana et al., 2009). It is possible to 348 
distinguish the presence of a B-band in AA2 and AA43, but not in AA44.  The late strain AMT 0023-34 349 
lost O-antigen production compared to the initial strain AMT 0023-30 (Fig. 6). Strains Pr335, U018a, 350 
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CPHL 9433 and 39177 belong to serotype O1 (Pirnay et al., 2009; Stewart et al., 2011) but show a 351 
slightly different O-antigen banding pattern in the present study (Fig. 6). The strain Jpn1563 has 352 
been described as non-typeable (Pirnay et al., 2009) and lacks B-band, which is used as the basis of 353 
P. aeruginosa serotyping.  354 
The LPS of strain 39016 showed a complete structure, with the production of both A- and B-355 
bands, but the pattern is distinct from that of PAO1.  Another abundant strain, RP1, showed a B-356 
band (Fig. 6).  In contrast, the common non-CF strains, 15108/1, 57P31PA showed A- and B- bands 357 
while strain 13121/1, showed B-bands only.  Two other non-CF strains, 96833S and 679 showed no 358 
O-antigen.  Strain 2192, recovered from a chronically infected patient in Boston has been previously 359 
described as devoid of LPS O-side chains (Mathee et al., 2008); however, we observed low level 360 
production of O-antigen side chains (Fig. 6). The genome of the CF strain TBCF10839 has been 361 
recently sequenced and harbors a serotype O4-like LPS biosynthesis gene cluster (Klockgether et al., 362 
2013).  Accordingly, LPS recovered from this strain shows a complete molecule, including O-antigen 363 
A- and B-bands. The clinical CF strains IST27 and IST27N have a similar LPS molecule.  LPS of these 364 
strains as well as of other clinical strains, C3719, DK2, AUS 52, AES-1R, AUS 23, RP1, 15108/1, 365 
57P31PA, 13121/1, KK1, A5803, 968333S and 679 have not been previously reported.  366 
 367 
Alginate production  368 
Strains AMT 0060-2, CHA, IST 27, 968333S and 2192 produced the highest levels of alginate (Table 1, 369 
Fig S3(a)), consistent with the previous observations of mucoidy for these strains (Leitao et al., 1996; 370 
Pier et al., 1983; Toussaint et al., 1993).   However, a few strains reported as being mucoid (AA43 371 
and NH57388A) or having upregulated alginate production (LES400) (Bragonzi et al., 2006; Hoffmann 372 
et al., 2005; Salunkhe et al., 2005), showed low levels of alginate.  Since growth of these strains on 373 
PIA plates did not generate mucoid colonies, it is likely that reversion of the mucoid phenotype has 374 
occurred upon subculturing.  Given that growth conditions affect stability of the mucoid phenotype 375 
and alginate production, the alginate production of IST 27 and three other strains grown on either LB 376 
or PIA plates was compared.  The mucoid strains AMT 0060-2 and IST27 revealed increased alginate 377 
production on PIA plates, while the non-mucoid strains produced low alginate amounts on PIA (Fig. 378 
S3(b)).  This phenotype correlated with virulence in G. mellonella; overnight cultures of IST27 mucoid 379 
and IST27N strains in LB showed comparable high virulence levels (LD50s of 0.37 and 0.36 for IST27 380 
and IST27N, respectively), while infection of the larvae with mucoid IST 27 from a PIA plate showed a 381 
substantial reduction in virulence (mean LD50 of 412 CFU), while the virulence of the non-mucoid 382 
strain was comparable with that observed when liquid broth was used (LD50 = 0.98).    383 
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 384 
Phage Typing  385 
Phage typing was carried out using well characterized, genome sequenced, bacteriophages 386 
belonging to various genus and with high lytic potency.  Two phages represented small podoviruses 387 
(LUZ7, LUZ19), three medium size myoviruses were from the Pbunalikevirus genus (LBL3, KT28, 388 
KTN6) and three belonged to giant myoviruses (φKZ, KTN4, PA5oct) were used (Table S1).  Phages 389 
LUZ19, φKZ, KTN4 and PA5oct require type IV pili for host infection; LUZ7, KT28, KTN6 are LPS-390 
dependent, whereas LBL3 cannot infect either wild type or the PAO1 mutants (Drulis-Kawa and 391 
colleagues, unpublished).   392 
 393 
All eight phages combined infected 86% of tested P. aeruginosa strains (Table 2). Single phages from 394 
the collection were sufficiently potent to propagate 23-46% of P. aeruginosa panel strains, 395 
regardless of geographic and infection origin.  The giant φKZ phage was the most potent, whereas 396 
the giant PA5oct infected only 10 strains.  Three CF strains (2192, 1709-12, RP1) and two non-CF 397 
strains (39016, 39177) were resistant to phage infection, while other three were only intermediate 398 
susceptible to LBL3 phage activity (all epidemic LES strains).  The analysis of phage typing in 399 
sequential strains based on phage receptor specificity gave varying results. The early CF strain, AA2, 400 
showed lower susceptibility to phage infection compared to late strains (AA43, AA44). In contrast, 401 
the susceptibility to phages did not change during 96-month colonization by AMT 0023 strains; these 402 
strains were infected by LPS dependent phages KT28, KTN6 and additionally by LBL3 phage.  The 403 
phage patterns were almost identical for the mucoid and non-mucoid pair IST 27 and IST 27N.   404 
 405 
 406 
Antibiotic resistance  407 
There was considerable variability in antibiotic susceptibilities within the panel (Table S4).  As 408 
expected, all strains were sensitive to colistin.  With the exception of ticarcillin-clavulanic acid and 409 
ofloxacin, proportionately more strains were susceptible than were resistant to the antibiotics 410 
tested.  In general, CF strains showed resistance to more antibiotics tested than non-CF strains, as 411 
expected.  Only five CF strains were susceptible to most, but not all antibiotics.  Among these 412 
susceptible strains, resistance was exhibited as follows:  DK2 was resistant to ticarcillin-clavulanic 413 
acid; AMT0023-30 and U018a were intermediate to aztreonam; RP1 resistant to piperacillin-414 
tazobactam and ticarcillin-clavulanic acid, while intermediate to aztreonam; the susceptibility of the 415 
non-mucoid strain ISTN towards aztreonam was considered indeterminate. Its mucoid variant was 416 
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susceptible to all antibiotics tested.  Not surprisingly, four of these susceptible CF strains were early 417 
paediatric strains. 418 
 419 
Presence of the ureC gene and quantification of urease activity  420 
Many bacteria utilise urease to survive in acidic conditions or as a nitrogen source.  It is essential to 421 
colonisation of many bacterial pathogens, including Helicobacter pylori and Pseudomonas spp. 422 
(Konieczna et al., 2012).   All strains produced urease, but it was variable and depended on culture 423 
conditions (Fig. S4).    424 
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DISCUSSION  425 
The international panel was assembled to reflect the diversity of sources and geographical origins 426 
across P. aeruginosa, providing a useful resource for researchers investigating P. aeruginosa 427 
pathogenesis or novel therapies against this organism (De Soyza et al., 2013).  The variability in 428 
phenotypes demonstrated in this study, highlights the diversity of the panel strains and P. 429 
aeruginosa itself.  Considerable genome diversity was previously documented in a series of chronic 430 
CF strains (Mowat et al., 2011). In this study, both CF and non-CF groups within the panel showed 431 
considerable phenotypic variability across the parameters measured.    432 
The only statistically significant difference between the CF and non-CF strains was the lower 433 
virulence of CF strains in the G. mellonella model.  This would not be unexpected as G. mellonella is 434 
an acute infection model and CF strains tend to accumulate mutations in virulence factors which 435 
may be important for acute infections (Cullen & McClean, 2015; Sousa & Pereira, 2014).  It has been 436 
demonstrated by others (Bragonzi et al., 2009; Lore et al., 2012) and also in this study that P. 437 
aeruginosa strains show reduced virulence over time of colonisation, most likely to avoid detection 438 
in the host.  Since CF strains generally were less virulent, the reduced virulence in G. mellonella may 439 
reflect an early adaptation during colonisation that would enable long-term colonisation and chronic 440 
infection.  Overall, the previously reported mucoid strains were among the least virulent strains 441 
examined with 96833S, 2192 and NH573888A each showing LD50 values between 500 and 250,000 442 
CFU.  LPS expression patterns also dramatically correlated with virulence for the majority of low 443 
virulence strains.  Most strains showing low levels of virulence (LD50s greater than 650 CFU) 444 
produced no or very little O-antigen.  However, there are other factors at play in the virulence 445 
mechanisms, as DK2 also showed no O-antigen expression, yet was considerably virulent in G. 446 
mellonella.  Virulence was independent of the serotypes represented in the panel with comparable 447 
very low LD50 values being observed for serotypes 1, 11, 12 and 17.     448 
The motility of the strains in the panel was highly variable.  The major difference was 449 
associated with the CF strains, which demonstrated a lack of motility characteristic of adaptation to 450 
chronic lung infection (Mahenthiralingam et al., 1994). In addition, although swarming motility has 451 
been characterised for various P. aeruginosa strains (Overhage et al., 2008; Rashid & Kornberg, 452 
2000) and UCBPP-PA14 (Tremblay & Deziel, 2010), only two panel strains demonstrated a true 453 
surface swarming phenotype. Swarming was highly dependent on growth media and conditions; 454 
hence the variation in phenotype observed compared to published literature may have been due to 455 
local test conditions.  The growth of the reference strains was also quite variable.  The transmissible 456 
strains LES B58, LES 400, LES 431 and C3719, showed unusual growth curves and interestingly, these 457 
four transmissible strains are also non-motile.   Another transmissible strain, AUS 52, was among the 458 
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group of strains with low culture density and was also non-motile. In contrast, transmissible strain 459 
DK2, was considerably motile and was grouped among the strains with high culture density.  The 460 
sequential strains AMT 0060-1, 2 and 3 and the AA2, AA43 and AA44 series each retained the 461 
relatively high culture density despite time of colonisation, indicating that this attribute is not 462 
altered over time of colonisation.       463 
Previous studies on biofilm formation were performed on a small number of the panel 464 
strains, but varied in the experimental parameters used, including culture media, time intervals 465 
tested and substrata used (Carter et al., 2010; Colvin et al., 2011; Junker & Clardy, 2007; Kukavica-466 
Ibrulj et al., 2008; Mikkelsen et al., 2013; Mulcahy et al., 2010; Zegans et al., 2012; Zhang et al., 467 
2013).  Our comprehensive panel strain analysis carried out over 3 days and using 3 different media 468 
indicated that all strains in the panel could form biofilms.  Swarming motility is inversely related to 469 
biofilm forming potential (Verstraeten et al., 2008); however no such trend was observed in this 470 
study since certain non-swarming strains were poor biofilm formers while others formed biofilms 471 
very well (Table 1 and Table 3S).  472 
Pyocyanin production is QS-controlled.  Fluctuations in pyocyanin production in a series of 473 
40 LES strains were reported, with overproduction during exacerbations in some CF patient strains 474 
and loss of pyocyanin during exacerbations in others (Fothergill et al., 2010).  Down-regulation of 475 
pyocyanin production was associated with a mucoid to non-mucoid switch (Ryall et al., 2014).  476 
Consistent with this, the mucoid strain IST 27 produced less pyocyanin relative to the spontaneous 477 
non-mucoid variant, IST 27N.  The most virulent strains produced the highest amount of pyocyanin 478 
and showed LD50 values in G. mellonella of less than 1 CFU at 24 h.  The relatively low levels of 479 
pyocyanin in the LES strains and other CF strains, AUS 52, AMT-0060 and bronchiectasis strain 480 
968333S correlates to the relative low virulence of these strains in G. mellonella.  A strong 481 
correlation between pyocyanin production and virulence was confirmed for the entire panel 482 
(Spearman rank correlation coefficient R = 0.36, p< 0.02). In contrast to earlier studies (Hendrickson 483 
et al., 2001; Sonnleitner et al., 2003), these data indicate that pyocyanin may contribute to virulence 484 
in the G. mellonella, as shown recently (Whiley et al., 2014).   485 
The mucoid phenotype is often reported as being unstable and non-mucoid variants can 486 
emerge both during culture and in the CF lung through suppressor mutations.  While investigating 487 
the mucoid strain IST27, care had to be taken to ensure that the mucoid phenotype was maintained.  488 
Culture in LB prior to virulence assays resulted in loss of the mucoid phenotype with a consequent 489 
enhancement of virulence. In order to maintain the mucoid phenotype, it is important to cultivate 490 
these strains in PIA as the difference between mucoid and non-mucoid phenotypes is not as distinct 491 
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when strains are grown on LB agar.  Care must be taken to select colonies with well-defined mucoid 492 
or non-mucoid phenotype (depending on the strain) to perform phenotypic characterisations.    493 
 Twitching motility is driven by extension, tethering and retraction of Type IV pili (Mattick, 494 
2002).  One of the late AMT-0060 strains (AMT 0060-2) showed both a lack of twitching motility and 495 
a resistance to the type IV-dependent phage Luz19, in contrast to both AMT0060-1 and AMT0060-3, 496 
confirming that type IV have been lost in this series.   Interestingly, both CF late strains (AA43 and 497 
AA44) did not differ in phage typing patterns from each other, which was confirmed by motility and 498 
LPS characterization. Moreover, the phenotypic modification during persistence of infection did not 499 
affect the activity of LBL3 phage in this series of paediatric strains.  The presence of twitching 500 
motility and identical LPS bands patterns confirmed the phage specificity to recognize type IV pili 501 
and LPS elements.  However, three of the 16 non-twitching strains (968333S, NH57388A and 502 
LMG14084) were susceptible to respectively four, three and two of IV-pili dependent phages (LUZ 503 
19, φKZ, KTN4 and PA5oct), indicating that they retained type IV receptors, though lacking the ability 504 
to twitch.  This could imply that although the type IV pili are present and act as phage receptors, 505 
they may have lost the motility function.  Alternatively, utilization of other receptors by phages 506 
cannot be ruled out.  507 
There are many strategies of bacterial resistance to phages, which may explain these results.  508 
Bacteriophages are highly specific, usually infecting strains within a single bacterial species. The 509 
specificity of interactions between phage and host cell surface receptors greatly influences the 510 
bacterial host range (Sulakvelidze et al., 2001; Weinbauer, 2004). P. aeruginosa receptors include 511 
LPS, outer membrane proteins, oligosaccharides, capsule, type IV fimbriae, flagella and sex pilus 512 
(Guttman, 2005).  It should be stressed that the most common mechanism of bacterial resistance to 513 
phage infection involves the lack, modification or masking of a target receptor, which blocks phage 514 
adsorption on the bacterial surface and results in complete loss of the ability to generate virus 515 
progeny. Moreover, bacteria can inhibit the phage cycle at other crucial steps of the propagation 516 
process, as recently reviewed (Drulis-Kawa et al., 2012; Labrie et al., 2010).  Overall, the phage 517 
typing patterns were consistent with twitching motility and LPS analysis.  The selected phages were 518 
active against most of CF and non-CF panel strains and the typing patterns correlated with bacterial 519 
cell surface elements presence such as IV-type pili and LPS structure. 520 
The considerable antibiotic resistance across the panel was expected, with CF strains 521 
generally showing resistance to more antibiotics than non-CF strains.  The only antibiotic that all 522 
strains were susceptible to was colistin, which remains a last-resort antibiotic for P. aeruginosa 523 
treatment.   Sensitivity to colistin is a hallmark of P. aeruginosa and consequently this antibiotic has 524 
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been used to distinguish P. aeruginosa strains from another CF associated pathogen, Burkholderia 525 
cepacia complex, which can grow in the presence of the colistin.  526 
In summary, this panel demonstrates the remarkable diversity seen across P. aeruginosa as a 527 
species.  The panel includes several transmissible strains, which generally show very low pyocyanin 528 
levels, low virulence and a lack of O-antigen or B-bands.  Furthermore it contains three sets of 529 
sequential strains which also show reduced virulence over time of colonisation, reduced pyocyanin 530 
and reduced O-antigen expression.  Finally, the population of CF strains in the P. aeruginosa 531 
reference panel shows lower virulence compared with the remaining strains in the panel.    532 
 533 
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Table 1. Summary table of phenotypes including growth density, virulence, motility, pyocyanin production and alginate production.  737 
Strain  
designation 
LMG 
number 
 
 
Short Description* 
Growth 
(Density at 15 
h) 
Virulence† Swimming
§ 
diameter (mm) 
Swarming diameter (mm) § 
Twitching 
diameter (mm) § Pyocyanin‡ 
Alginate 
+/-  
LB 0.5% agar BSM-G 0.5% agar 
LES B58 27622 CF, transmissible 
 
L L 17.5 - - - H - 
LES 400 27623 L L - - - - VL - 
LES 431 27624 L L - - - - VL - 
C3719 27625 L L - - - - H - 
DK2 27626 CF, transmissible, early isolate H L 53.5 19 12.5 12 L - 
AES-1R 27627 CF transmissible paediatric L H 51 - - - VL - 
AUS23 27628 CF transmissible adult L L 52.5 - - 9  - 
AUS52 27629 L H - - - -  - 
AA2 27630 Early CF H H 67 11 10 24.5 H - 
AA43 27631 Late CF H H 67 15.5 9 25 VL - 
AA44 27632 Late CF H H 60 14.5 7.5 29.5 VL - 
AMT 0023-30 27633 Paediatric CF early H H 53.5 12 9 27.5 H - 
AMT 0023-34 27634 Paediatric CF late  I L 53.5 - - - VL - 
AMT 0060-1 27635 Paediatric CF late H L 46.5 15.5 8.5 12.5 L - 
AMT 0060-2 27636 Paediatric CF late H H 31.5 - - - L + 
AMT 0060-3 27637 Paediatric CF early H L 61 24.5 14 12.5 H - 
PAO1* (ATCC 15692) 27638 Non CF H H 60.5 28 18.5 23.5 H - 
UCBPP-PA14 27639 Non CF L H 62.5 24 16.5 11 VL - 
PAK 27640 Non CF H H 60 12.5 10 17 VL - 
CHA 27641 CF H H 80 25.5 18 19.5 L + 
IST 27 mucoid 27643 CF H M 51.5 13.5 Swarming 5.5 L + 
IST 27 non-mucoid 27644 CF H H 72 21.5 Swarming 22.5 L - 
968333S 27645 Non-CF Bronchiectasis L L - - - - VL + 
679 27646 Non-CF urine H H 57 13.5 17.5 - H - 
25 
 
39016 27647 Non-CF eye H H 75 22.5 11 30.5 H  
2192 27648 CF H L Spread all over plate 11 21.5 - H + 
NH57388A 27649 CF L L 7.5 9 8.5 - VL - 
1709-12 27650 Non CF clinical H H 29.5 7.5 - - H - 
Mil 162 27651 Non-CF burn L H 62.5 - - - VL - 
Jpn 1563 27652 Water H H 25 16.5 15 38 L - 
LMG 14084 27653 Water H H 58.5 14.5 - - H - 
Pr335 27654 Hospital environment H H 53.5 16 11.5 18.5 H - 
U018a 27655 CF H H 53.5 28.5 16.5 22.5 H - 
CPHL 9433 27656 Tobacco plant H H 66 13.5 7.5 11.5 H - 
RP1 27657 CF H H 65 26 8.5 15.5 VL - 
15108/1 27658 Non-CF ICU  H H 61 34 17.5 14.5 VL - 
57P31PA 27659 Non-CF, COPD H H 68.5 31 14 14 L - 
13121/1 27660 Non-CF ICU H H 54.5 16 9.5 6.5 VL - 
39177 27661 Non-CF eye H H 48.5 15.5 8 19.5 H - 
KK1 27662 CF H H 74.5 17.5 11 21 L - 
A5803 
27663 Community acquired 
pneumonia 
H H 
55.5 14 10.5 14 
H - 
TBCF 10839 27664 CF H H 67.5 36.5 32.5 - H - 
   738 
* Full description in (De Soyza et al., 2013). † Virulence summarised as “H” representing high virulence, LD50 <5 CFU; “M” representing medium virulence, 739 
i.e LD50 >5<650 CFU and “L”>representing low virulence, LD50>650 CFU.   ‡ Pyocyanin summarised as high > 0.1, low <0. 1 and very low <0.05; §  Shading 740 
designates “highly motile”. 741 
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Table 2:  Phage typing of P. aeruginosa panel.*  742 
Strain designation Source Phages 
  LUZ 7 LUZ 19 LBL 3 KT28 KTN6 φKZ KTN4 PA5oct 
LES 400 CF 
  
+ 
     
LES 431 CF 
  
+ 
     
LES B58 CF 
  
+ 
     
C3719 CF +/- 
 
+/- +/- +/- 
   
DK2 CF 
 
+/- 
   
+/- +/- 
 
AES-1R CF +/- +/- 
      
AUS 23 CF 
 
+/- 
   
+ 
  
AUS 52 CF +/- 
 
+/- +/- +/- +/- 
  
AA2 CF +/- 
       
AA43 CF +/- 
  
+/- +/- +/- + +/- 
AA44 CF +/- 
  
+/- +/- +/- 
 
+/- 
AMT 0023-30 CF + 
 
+/- +/- +/- 
 
+ 
 
AMT 0023-34 CF 
  
+/- +/- +/- 
   
AMT 0060-1 CF 
 
+/- +/- 
     
AMT 0060-2 CF 
  
+/- 
     
AMT 0060-3 CF 
 
+/- +/- 
   
+/- 
 
PAO1* CLIN +/- +/- 
 
+/- +/- +/- +/- +/- 
UCBPP-PA14 CLIN 
  
+ 
  
+/- 
  
PAK CLIN +/- +/- +/- +/- +/- +/- +/- 
 
CHA CF +/- +/- +/- +/- +/- 
 
+/- + 
IST 27 mucoid CF +/- +/- 
  
+/- +/- +/- 
 
IST 27N CF +/- +/- 
 
+ +/- +/- +/- 
 
968333S CLIN +/- +/- 
   
+/- +/- + 
679 CLIN +/- 
  
+/- +/- 
   
39016 CLIN 
        
2192 CF 
        
NH57388A CF 
 
+/- +/- 
  
+/- 
 
+ 
1709-12 CLIN 
        
Mi162 CLIN +/- 
       
Jpn 1563 ENV +/- +/- 
   
+/- +/- +/- 
LMG 14084 ENV 
 
+/- 
   
+ 
  
Prr 335 ENV 
 
+/- 
   
+/- +/- 
 
U018a CF 
 
+/- 
 
+/- + 
  
+ 
CPHL 9433 ENV 
  
+/- 
 
+/- + 
  
RP1 CF 
        
15108/1 CLIN 
 
+/- 
   
+ +/- 
 
57P31PA CLIN 
 
+/- 
  
+/- 
   
13121/1 CLIN 
     
+/- 
  
39177 CLIN 
        
KK1 CF + 
 
+/- 
 
+/- 
  
+ 
A5803 CLIN +/- +/- +/- 
 
+/- + + + 
TBCF10839 CF 
    
+/- + 
  
*Symbols:   + indicates confluent clear lysis; +/- indicates confluent opaque lysis; empty boxes represent lack of 743 
activity. 744 
745 
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Figure Legends:  746 
Fig. 1.  Growth of P. aeruginosa panel strains. a) Maximum culture density reached at 15 h growth. 747 
The distribution of the maximum culture density data at 15 hours growth were visualised using a 748 
boxplot displaying median, upper quartile, lower quartile, maximum and minimum values.  Data 749 
points for each of the strains are included on the plot. The black brackets illustrate three broad 750 
strain groupings (high, intermediate and low culture density) and the strain names are listed in order 751 
(highest to lowest Max OD) to the right of the boxplot.  b)  Growth parameters at 30 h growth. The 752 
distribution of the growth parameter data (length of lag phase, growth rate and maximum culture 753 
density reached) were visualised using boxplots which display the median, upper quartile, lower 754 
quartile, maximum and minimum values. Outliers are indicated by open circles.  The 36 strains 755 
included in the analysis have either been grouped together (All) or by isolation source (CF; CLIN; 756 
ENV).  Strain names have been included next to outliers.  Each experiment was performed twice with 757 
four technical replicates per strain. 758 
Fig 2.  Virulence in G. mellonella. Virulence was measured in terms of % survival of groups of 6 759 
larvae in at least two independent experiments.  The mean LD50 (the CFU that resulted in 50% killing 760 
of the larvae) at 24 hours is presented +/- standard deviation.  761 
Fig. 3.  AHL expression. Signal obtained using the P. aeruginosa QSIS2 biosensor (a) or the E. coli 762 
JB523 biosensor (b) with supernatants from 24 h P. aeruginosa cultures.  The results are presented 763 
as mean +/- SEM of four independent replicates.  *Significantly different from negative control (p < 764 
0.05).   765 
Fig. 4.  Biofilm formation as determined by crystal violet staining. Results are presented as mean 766 
maximal absorbance at A570nm for each strain (+/- standard deviation) from at least two 767 
independent experiments.  The medium that resulted in maximal biofilm formation together with 768 
the timepoint at which this was registered is identified in parenthesis, where 1= 24 h, 2= 48 h and 3= 769 
72 h).    770 
Fig. 5.   Pyocyanin production. Pyocyanin was extracted in chloroform, back-extracted in HCl and 771 
measured at 520nm.  The results are the means of at least two independent experiments performed 772 
in duplicate ± SEM.   773 
Fig. 6.  LPS profiles following SDS-PAGE. LPS was extracted from overnight cultures at OD600 of 2.0 774 
and separated on 14% polyacrylamide/Glycine-SDS gels.  The majority of strains express smooth 775 
forms of LPS and display a ladder profiles that are strain-specific. 776 
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Figure 1 (a) 778 
 779 
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Fig 1(b) 780 
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Figure 2 785 
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Figure 3:   790 
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Figure 4  796 
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Figure 5   798 
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Supplemental information.  802 
 803 
Table 1S:   Phage used for phage typing 804 
 805 
Bacteriophage Family Description Genome 
size (kbp) 
GenBank 
Accession 
number 
LUZ7 Podoviridae N4likevirus 74.9 NC_013691.1 
LUZ19 Podoviridae Phikmvlikevirus 43.5 NC_010326.1 
LBL3  Myoviridae Pbunalikevirus 64.4 NC_011165.1 
φKZ, ,  Myoviridae Phikzlikevirus 230.3 AF399011.1 
φKT28,  Myoviridae Pbunalikevirus 66.4 KP340287 
φKTN6,  Myoviridae Pbunalikevirus, 66.4 KP340288 
φKTN4,  Myoviridae Phikzlikevirus, 279.7 pending 
PA5oct, ,  Myoviridae NovelGiant 287.2 Pending 
 806 
  807 
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 808 
Table 2S. Growth parameters of 36 Pseudomonas aeruginosa international reference 809 
panel strains at 30 hours growth 810 
 811 
Panel # Source Strain Growth rate 
(h
-1
) 
Lag phase 
(hrs) 
Max Log10 OD    
(420-580 nm) 
5 CF DK2 0.07 4.96 0.36 
6 CF AES-1R 0.02 6.76 0.30 
7 CF AUS23 0.02 3.98 0.19 
8 CF AUS52 0.01 5.50 0.16 
9 CF AA2 0.12 5.22 0.38 
10 CF AA43 0.10 5.81 0.34 
11 CF AA44 0.05 4.65 0.31 
12 CF AMT 0023-30 0.10 4.73 0.35 
13 CF AMT 0023-34 0.03 7.93 0.29 
14 CF AMT 0060-1 0.06 5.37 0.34 
15 CF AMT 0060-2 0.05 6.22 0.36 
16 CF AMT 0060-3 0.06 4.55 0.36 
17 CLIN PAO1* (ATCC 15692) 0.07 5.14 0.37 
18 CLIN UCBPP-PA14 0.02 3.64 0.26 
19 CLIN PAK 0.03 3.68 0.36 
20 CF CHA 0.04 4.86 0.34 
22 CF IST 27 mucoid 0.04 5.77 0.33 
23 CF IST 27 non-mucoid 0.05 5.80 0.33 
24 CLIN 96833S 0.01 8.81 0.13 
25 CLIN 679 0.10 6.74 0.35 
26 CLIN 39016 0.05 6.52 0.37 
27 CF 2192 0.06 8.03 0.37 
29 CLIN 1709-12 0.07 5.76 0.38 
31 ENV Jpn 1563 0.05 6.26 0.35 
32 ENV LMG 14084 0.09 5.76 0.35 
33 ENV Pr335 0.10 4.85 0.34 
34 CF U018a 0.07 5.18 0.34 
35 ENV CPHL 9433 0.13 5.52 0.37 
36 CF RP1 0.08 4.60 0.37 
37 CLIN 15108/1 0.05 6.92 0.33 
38 CLIN 57P31PA 0.05 4.84 0.39 
39 CLIN 13121/1 0.05 5.50 0.34 
40 CLIN 39177 0.10 4.98 0.34 
41 CF KK1 0.06 5.42 0.36 
42 CLIN A5803 0.10 4.96 0.36 
43 CF TBCF 10839 0.07 7.48 0.37 
 812 
  813 
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Table 3S.  Biofilm formation across the panel in MHB (A), LB (B) or M63 minimal medium 814 
(C) as determined by crystal violet staining at 24, 28 and 72 h. The values correspond to  815 
average absorbance (AV) and Standard deviation (STD).    816 
A 817 
Strain MH-24h  MH-48h  MH-72h  
       
 AV STD AV STD AV STD 
LES B58 0.25 0.04 0.18 0.04 0.24 0.06 
LES 400 0.17 0.06 0.24 0.07 0.34 0.17 
LES 431 0.06 0.02 0.14 0.06 0.16 0.06 
C3719 0.64 0.22 1.57 0.38 1.69 0.42 
DK2 0.29 0.11 0.34 0.11 0.23 0.06 
AES-1R 0.09 0.01 0.60 0.10 0.19 0.04 
AUS23 0.30 0.15 0.46 0.28 0.16 0.14 
AUS52 0.48 0.21 0.56 0.13 1.70 0.17 
AA2 0.32 0.18 0.11 0.05 0.14 0.14 
AA43 0.10 0.07 0.44 0.10 0.11 0.06 
AA44 0.13 0.03 0.11 0.05 0.07 0.14 
AMT 
0023-30 
0.50 0.25 0.31 0.13 0.16 0.08 
AMT 023-
34 
0.29 0.10 0.12 0.05 0.44 0.21 
AMT 
0060-1 
0.66 0.15 1.62 0.16 1.87 0.15 
AMT 
0060-2 
0.17 0.15 0.09 0.02 0.17 0.14 
AMT 
0060-3 
0.43 0.08 0.00 0.00 0.26 0.14 
PAO1 0.31 0.06 0.19 0.02 0.23 0.05 
PA-14 1.46 0.38 0.74 0.17 0.43 0.16 
PAK 0.58 0.22 0.34 0.12 0.23 0.13 
CHA 1.10 0.59 0.54 0.23 0.28 0.09 
IST 27 
mucoid 
1.49 0.39 0.48 0.09 0.17 0.04 
IST 27 N 0.96 0.36 1.15 0.31 0.87 0.50 
968333S 0.10 0.06 0.14 0.16 0.11 0.15 
679 0.27 0.04 0.53 0.16 0.96 0.47 
39016 1.38 0.27 0.22 0.06 0.16 0.13 
2192 0.50 0.20 0.71 0.46 0.92 0.23 
NH57388
A 
0.03 0.01 0.13 0.06 0.24 0.29 
1709-12 0.97 0.34 0.43 0.09 0.26 0.07 
Mi 162 0.05 0.04 0.04 0.02 0.02 0.01 
Jpn 1563 0.44 0.18 0.27 0.04 0.22 0.02 
LMG 
14084 
0.28 0.07 0.11 0.01 0.04 0.00 
Pr335 0.48 0.20 0.32 0.05 0.23 0.09 
U018a 0.54 0.07 0.19 0.02 0.09 0.02 
CPHL 
9433 
0.41 0.14 0.41 0.09 0.25 0.03 
38 
 
RP1 0.66 0.17 0.36 0.05 0.05 0.01 
15108/1 0.29 0.07 0.35 0.16 0.14 0.05 
57P31PA 1.33 0.26 0.22 0.07 0.16 0.03 
13121/1 NT NT 0.13 0.04 0.05 0.02 
39177 NT Nt 0.15 0.04 0.09 0.03 
KK1(d1) 1.16 0.24 0.33 0.08 0.19 0.04 
TBCF1083
9(d1) 
0.47 0.13 0.10 0.04 0.11 0.06 
 818 
B 819 
 LB-24h  LB-48 h  LB-72 h  
 AV STD AV STD AV STD 
LES B58 0.90 0.30 0.21 0.06 0.11 0.03 
LES 400 0.28 0.09 0.37 0.17 0.17 0.08 
LES 431 0.05 0.01 0.07 0.06 0.07 0.06 
C3719 0.19 0.09 0.18 0.05 0.52 0.14 
DK2 1.47 0.33 0.91 0.21 0.69 0.12 
AES-1R 0.85 0.28 0.36 0.04 0.15 0.04 
AUS23 0.59 0.12 0.55 0.16 0.17 0.06 
AUS52 0.63 0.23 0.33 0.15 0.21 0.06 
AA2 0.52 0.17 0.11 0.04 0.15 0.04 
AA43 0.07 0.03 0.19 0.06 0.06 0.06 
AA44 0.11 0.03 0.47 0.13 0.11 0.06 
AMT 
0023-30 
0.87 0.26 0.45 0.14 0.16 0.10 
AMT 023-
34 
1.01 0.30 1.93 0.40 1.01 0.52 
AMT 
0060-1 
0.19 0.04 0.29 0.06 0.29 0.07 
AMT 
0060-2 
0.28 0.05 0.12 0.03 0.12 0.02 
AMT 
0060-3 
1.35 0.26 0.32 0.11 0.16 0.08 
PAO1 1.01 0.10 0.21 0.06 0.13 0.07 
PA-14 1.20 0.35 1.31 0.33 0.81 0.35 
PAK 1.48 0.30 0.80 0.16 0.84 0.10 
CHA 2.18 0.46 1.24 0.44 0.58 0.13 
IST 27 
mucoid 
1.13 0.49 0.75 0.28 0.50 0.23 
IST 27 N 1.37 0.37 1.06 0.38 0.78 0.46 
968333S 1.45 0.54 1.48 0.37 0.54 0.45 
679 0.82 0.42 0.37 0.28 0.23 0.15 
39016 1.56 0.24 0.34 0.11 0.19 0.18 
2192 0.47 0.19 0.45 0.11 0.26 0.16 
NH57388
A 
1.18 0.30 0.66 0.11 0.52 0.11 
1709-12 0.88 0.07 0.26 0.07 0.13 0.03 
Mi 162 0.15 0.07 0.22 0.10 0.11 0.04 
Jpn 1563 0.41 0.09 0.63 0.11 0.40 0.07 
LMG 
14084 
0.25 0.09 0.10 0.02 0.04 0.03 
39 
 
Pr335 0.47 0.07 0.33 0.08 0.23 0.05 
U018a 0.42 0.07 0.14 0.03 0.12 0.03 
CPHL 
9433 
0.22 0.07 0.72 0.13 0.66 0.12 
RP1 0.23 0.06 0.38 0.07 0.27 0.03 
15108/1 0.45 0.12 0.31 0.07 0.14 0.03 
57P31PA 0.19 0.04 0.38 0.06 0.34 0.04 
13121/1 0.58 0.04 0.12 0.01 0.13 0.07 
39177 0.69 0.06 0.21 0.06 0.21 0.04 
KK1(d1) 0.72 0.11 0.39 0.09 0.32 0.09 
A5803(d1) 0.25 0.07 0.14 0.05 0.17 0.09 
TBCF1083
9(d1) 
0.67 0.08 0.38 0.09 0.19 0.06 
 820 
 821 
C 822 
 M63-24 
h 
 M63-48 
h 
 M63-72 
h 
 
 AV STD AV STD AV STD 
LES B58 0.07 0.01 0.05 0.01 0.10 0.02 
LES 400 0.22 0.04 0.19 0.05 0.13 0.03 
LES 431 0.05 0.02 0.07 0.02 0.15 0.05 
C3719 0.04 0.02 0.19 0.08 0.42 0.11 
DK2 1.63 0.25 0.40 0.14 0.35 0.12 
AES-1R 0.50 0.10 0.32 0.06 0.15 0.08 
AUS23 0.30 0.09 1.06 0.14 0.49 0.09 
AUS52 1.12 0.43 0.47 0.17 0.67 0.16 
AA2 0.46 0.09 0.37 0.05 0.97 0.29 
AA43 0.18 0.07 0.43 0.11 0.08 0.06 
AA44 0.18 0.05 1.59 0.40 0.26 0.09 
AMT 
0023-30 
0.40 0.10 0.38 0.07 0.52 0.59 
AMT 023-
34 
1.32 0.28 1.43 0.80 1.05 0.40 
AMT 
0060-1 
0.31 0.09 0.51 0.10 0.66 0.10 
AMT 
0060-2 
0.14 0.13 0.14 0.17 0.33 0.05 
AMT 
0060-3 
0.73 0.40 0.57 0.19 0.40 0.15 
PAO1 0.44 0.10 0.34 0.04 0.37 0.10 
PA-14 3.00 0.08 2.00 0.30 1.31 0.26 
PAK 1.18 0.13 0.92 0.12 1.31 0.26 
CHA 0.19 0.04 0.60 0.09 0.23 0.08 
IST 27 
mucoid 
0.67 0.15 0.35 0.14 0.16 0.08 
IST 27 N 0.93 0.08 0.61 0.11 0.38 0.12 
968333S 0.10 0.07 1.03 0.17 0.86 0.16 
679 0.53 0.23 0.72 0.47 0.53 0.42 
39016 0.49 0.10 0.94 0.08 0.75 0.08 
2192 0.47 0.07 0.44 0.16 0.56 0.17 
40 
 
NH57388
A 
0.16 0.03 0.03 0.01 0.04 0.01 
1709-12 1.28 0.32 0.22 0.04 0.11 0.03 
Mi 162 0.53 0.17 0.60 0.17 0.54 0.12 
Jpn 1563 0.78 0.28 0.44 0.10 0.17 0.05 
LMG 
14084 
0.15 0.03 0.10 0.02 0.05 0.01 
Pr335 0.37 0.13 0.41 0.14 0.25 0.10 
U018a 0.31 0.10 0.27 0.09 0.24 0.12 
CPHL 
9433 
0.24 0.05 0.37 0.06 0.24 0.04 
RP1 0.15 0.03 0.19 0.05 0.11 0.02 
15108/1 0.35 0.17 0.29 0.05 0.26 0.08 
57P31PA 0.15 0.02 0.19 0.04 0.18 0.04 
13121/1 0.97 0.31 0.21 0.09 0.28 0.07 
39177 1.07 0.38 0.21 0.10 0.17 0.05 
KK1(d1) 0.70 0.14 0.44 0.07 0.18 0.02 
A5803(d1) 0.95 0.19 0.60 0.12 0.57 0.16 
TBCF1083
9(d1) 
0.52 0.11 0.50 0.10 0.34 0.09 
 823 
 824 
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Table 4S.   Antibiotic resistance of the panel strains 
 
EUCAST Breakpoint 
      
  
     S ≤ 4 4 0.5 1 16 16 8 8 8 8 2 0.5 4 8 1 16 
I  -  - 1  2 - 16  -  -  -  -  -  -  4 - 8 1  - 16 2  - 
R > 4 4 1 16 16 16 8 8 8 8 8 1 4 16 2 16 
 
                                
 
Genta
micin 
Coli
stin 
Oflox
acin 
Aztreo
nam 
Pipera
cillin 
Piperac
illin-
tazoba
ctam 
Cefoper
azone 
Ceftazi
dime 
Cefep
ime 
Cefop./
sulb 
Merope
nem 
Ciproflo
xacin 
Tobra
mycin 
Amik
acin 
Levoflo
xacin 
Ticarc
illin-
clavul
anic 
acid 
 
                                
LES B58 R S R R S R S R R S Ind R S R R R 
LES 400 R S R R S S S R R S I  R S R R R 
LES 431 R S R R R R R R R R I R S R R R 
C3719 S S R R R R R R R S R R S Ind R R 
DK2 S S S I S S S S S S S S S S S R 
AES-1R  R S R S R S R S R R R S S R S R 
AUS23 S S R I Ind S R S S R S S S S S R 
AUS52 R S R S S S S S R S R R R S R S 
AA2 S S S S S R R S S S S S S S S R 
AA43 S S R Ind S R S S R S S S S S S R 
AA44 S S R I R R R S S S S S S S S R 
AMT 
0023-30 S S 
S 
I S S 
S 
S S 
S 
S S S S S S 
AMT 
0023-34 R S 
R 
S S S 
S 
S S 
S 
S Ind R R R S 
AMT 
0060-1 S S 
R 
S S S 
S 
S S 
S 
S I  S S R S 
AMT 
0060-2 S S 
R 
I S S 
S 
S S 
S 
S S S S S S 
42 
 
AMT 
0060-3 S S 
I 
I S S 
S 
S S 
S 
S S S S S R 
PAO1*(
ATCC 
15692) S S 
S 
I S S 
S 
S S 
S 
S S S S S S 
UCBPP-
PA14 S S 
S 
I S S 
S 
S S 
S 
S S S S S R 
PAK S S S I S S S S S S S S S S S R 
CHA R S I I S S S S S S S S S S S R 
IST 27 
mucoid S S S S S S S S S S S S S S S S 
IST 27N 
S S S Ind S S S S S S S S S S S S 
968333S R S I R R R R R R S I S S S S R 
679 R S R I S S S S S S I S S S S R 
39106 
S S I I S S S S S S S S S S S R 
2192 
S S S S Ind S S S S S S S S S S S 
NH5738
8A S S R Ind R S R R R S S R S S R R 
1709-12 R S R R R R R R R R R R R R R R 
Mi 162 R S R R R R R R R R R S R Ind S R 
Jpn 
1563 S S 
R 
I S S 
R 
S S 
S 
S S S S S R 
LMG 
14084 S S 
S 
I S S 
S 
S S 
S 
S S S S S R 
Pr335 S S S I S S S S S S S S S S S R 
U018a S S S I S S S S S S S S S S S R 
CPHL 
9433 S S 
I 
I S S 
S 
S S 
S 
S S S S S S 
RP1 S S S I S R S S S S S S S S S R 
15108/1 S S R I S R R S S R I S S S S R 
57P31P
A S S 
I 
I S S 
S 
S R 
S 
S S S S S R 
13121/1 S S R I R R R 8 S R S R S S R R 
39177 S S I I S S S S S S S S S S R R 
KK1 S S S I S S S S S S S S S S S R 
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A5803 S S R I S R S S R S S R S S R R 
TBCF10
839 S S 
I 
I S R 
R 
S S 
S 
S S S S R R 
PSA 
10662 S S NT S NT S NT S S NT S S S S S S 
 
Antibiotic susceptibilities are shown as follows:  S susceptible, R Resistant, I Intermediate, Ind indeterminate, i.e there was no agreement between the 
two independent methods used, NT Not tested 
  
44 
 
Supplemental Figures:  
Fig S1: Growth curves panel strains.  The growth of the 42 panel strains in MHB at 37°C was monitored using the Bioscreen C to measure culture optical 
density over 48 hours.  Each experiment was performed twice with four technical replicates per strain, per experiment.   
Fig. S2.  Swimming, swarming and twitching motilities. Representative images of the levels of swimming, swarming on LB agar, swarming on BSM-G agar 
and twitching motility exhibited by panel strains. 
Fig. S3.  Alginate production.  a) Alginate production from cells grown in LB.  b)  Comparison of alginate production of selected mucoid and non-mucoid 
strains grown in LB agar (black bars) or PIA (grey bars).  The results presented are the means ± SD of at least two independent analyses using at least two 
independent cultures of the same strain.   
Fig. S4.  Urease Activity.   Urease activity of Pseudomonas aeruginosa strains on Christensen broth in the presence of urea.  Results represent the means of 
three independent experiments + SD.   
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Figure S2  
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Fig. 3(a)
 
Fig. 3(b)
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Figure S4  
 
 
0
0.2
0.4
0.6
0.8
1
1.2
LE
S 
B
5
8
LE
S 
4
0
0
LE
S 
4
3
1
C
3
7
1
9
D
K
2
A
ES
-1
R
A
U
S2
3
A
U
S5
2
A
A
2
A
A
4
3
A
A
4
4
A
M
T 
 0
0
2
3
-3
0
A
M
T 
0
0
2
3
-3
4
A
M
T 
0
0
6
0
-1
A
M
T 
0
0
6
0
-2
A
M
T 
0
0
6
0
-3
P
A
O
1
 (
A
TC
C
 1
5
6
9
2
)
U
C
B
P
P
-P
A
1
4
P
A
K
C
H
A
IS
T 
2
7
 m
u
co
id
IS
T 
2
7
N
9
6
8
3
3
3
S
6
7
9
3
9
0
1
6
2
1
9
2
N
H
5
7
3
8
8
A
1
7
0
9
-1
2
M
i 1
6
2
Jp
n
 1
5
6
3
LM
G
 1
4
0
8
4
P
r3
3
5
U
0
1
8
a
C
P
H
L 
9
4
3
3
R
P
1
1
5
1
0
8
/1
5
7
P
3
1
P
A
1
3
1
2
1
/1
3
9
1
7
7
K
K
1
A
5
8
0
3
TB
C
F 
1
0
8
3
9
U
re
as
e
 a
ct
iv
it
y 
(5
6
0
n
m
)
